Alzamend Neuro, Inc. ALZN
Set alert
1.42 USD +0.11 +8.40%
As of Nov 3, 12:00 PM ET
1.27 Day range 1.50
0.84 52-week range 2.61
- YTD
- -21.98%
- 1 year
- -44.09%
- Open
- 1.28
- Prev close
- 1.31
- Mkt cap
- 6.85M
- Vol
- 123.46K
- Avg vol
- 79.81K
- EPS
- -2.30
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.27
- High
- 1.50
- Forward P/E
- -0.26
- Beta
- -0.04
- Short ratio
- 1.03
- Inst. own
- 0.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Sep 11, 2024
- 50-d avg
- 1.42
- 200-d avg
- 4.08
- 1y target
- 32.00
2Y chart
Events in this range
- Nov 11, 2024Rating: Ascendiant Capital · Buy → Buy
- Dec 11, 2024Earnings: -0.4; estimate -2.38; surprise 83.19%
- Dec 16, 2024Rating: Ascendiant Capital · Buy → Buy
- May 12, 2025Split: 1 for 9
Signals (73)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 4 days ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| RSI: Overbought | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 2 months ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 15, 2026 | 6 months ago |
Newest 20 of 73.
Key statistics
- Market cap
- 6.47M
- Enterprise value
- 3.47M
- Trailing P/E
- 0.00
- Forward P/E
- -0.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -138.31
- Beta
- -0.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -3.36M
- Total cash
- 1.19M
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 5.43M
- Short % of float
- 3.11%
- 50-day average
- 1.42
- 200-day average
- 4.08
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 11, 2024
Expected Sep 11, 2024. Consensus EPS estimate -0.29.
Financials — quick view
ALZN Revenue — quarterly 0
ALZN Net income — quarterly -3.03M
ALZN EPS — quarterly -0.68
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 11, 2024 | Oct 1, 2024 | -2.38 | -0.40 | +1.98 | +83.19% |
| Sep 11, 2024 | Jul 1, 2024 | 0.00 | -1.25 | — | — |
| Sep 11, 2024 | Jul 1, 2024 | 0.00 | — | — | — |
| Mar 25, 2024 | Jan 1, 2024 | 0.00 | — | — | — |
| Mar 25, 2024 | Jan 1, 2024 | 0.00 | -3.80 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 11, 2024 | Ascendiant Capital | main | Buy | Buy |
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alzamend.com
News
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?
- Alzamend Neuro Regains Nasdaq Compliance
- Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY
- Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026
- Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
- Palo Alto To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
- Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26
- Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop
- Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Your note
Sign in to keep a note on ALZN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AULT MILTON C III | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 18, 2024 | 0 |
| GUSTAFSON MARK GARLAND | Director | Sale | Mar 30, 2022 | 60,000 |
| HORNE WILLIAM B | Director | Conversion of Exercise of derivative security | Feb 23, 2023 | 1,000,000 |
| JACKMAN STEPHAN | Chief Executive Officer | Purchase | Apr 27, 2023 | 45,500 |
| KATZOFF DAVID J | Chief Financial Officer | Purchase | Sep 25, 2023 | 81,000 |
| MCGRATH LYNNE FAHEY | Director | Sale | Dec 25, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 0.31% | 16,601 | 19.75K | Sep 29, 2024 |
| Truist Financial Corp | 0.29% | 15,498 | 18.44K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 4,167 | 4.96K | Sep 29, 2024 |
| Blackrock Inc. | 0.07% | 3,973 | 4.73K | Sep 29, 2024 |
| Wells Fargo & Company | 0.02% | 1,000 | 1.19K | Sep 29, 2024 |
| Corecap Advisors, LLC | 0.01% | 708 | 842 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.14% | 7,854 | 9.35K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.07% | 3,848 | 4.58K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 2,189 | 2.60K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 999 | 1.19K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.01% | 705 | 838 | Oct 30, 2024 |